TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24552372
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (7 g leucine, 93 kcal, 14.5 g whey-based protein)
Study: 24552372
Drug: Isocaloric isonitrogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric isonitrogenous control (0.3 g LEU, 93 kcal, 11.3 g collagen protein)
Study: 27993418
Drug: Intravenous Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ketorolac 30 mg
Study: 27993418
Drug: Rescue analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesic (Intravenous morphine 0.1 mg/kg)
Study: 19956961
Drug: Laparoscopic ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic ovarian drilling (LOD) and CC
Study: 7738616
Drug: No BK
Approvals — FDA: no, EMA: no, PMDA: no
Description: No BK virus excretion
Study: 17584555
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg, 3 times a day)
Study: 11530028
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg initial dose, titrated to 80 mg if needed)
Study: 9506347
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with or without chemotherapy
Study: 9506347
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with chemotherapy
Study: 7997863
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g paracetamol (as propacetamol) intravenously
Study: 3287974
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 perioperative doses of 2 g)
Study: 3287974
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g single preoperative dose)
Study: 23233651
Drug: HER2 positive
Normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2 positive pre-treatment biopsies
Study: 17200303
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with a sling
Study: 10572606
Drug: MACOP-B (6-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACOP-B (6-drug weekly chemotherapy regimen for 12 weeks)
Study: 1852297
Drug: Methoxybutropate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxybutropate (300 mg three times a day for eight weeks)
Study: 30403976
Drug: Early Oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Oral Feeding (EOF) group
Study: 30403976
Drug: Late Oral
Normalized name: Adalate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late Oral Feeding (LOF) group
Study: 27822013
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of clopidogrel/aspirin 75/100 mg
Study: 27822013
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of individual formulations (clopidogrel 75 mg and aspirin 100 mg)
Study: 21420744
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of psychotropic drugs
Study: 21420744
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not ceasing drug use)
Study: 21041350
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention including patient education and choice of medication, therapy, or both.
Study: 10743445
Drug: placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo suppository
Study: 1553891
Drug: Bepridil 200
Normalized name: bepridil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 200 mg
Study: 1553891
Drug: Bepridil 300
Normalized name: bepridil 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 300 mg
Study: 1553891
Drug: Bepridil 400
Normalized name: bepridil 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 400 mg
Study: 2581680
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intrathecal morphine (Group B)
Study: 2581680
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intrathecal morphine (Group C)
Study: 2581680
Drug: Prilocaine 100
Normalized name: prilocaine 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 100 mg (Group A, Control)
Study: 20878324
Drug: Intensive Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Insulin Therapy (IIT)
Study: 20878324
Drug: Conventional Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional Insulin Therapy (CIT)
Study: 10356917
Drug: Cortexin delivered
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexin delivered via nasal electrophoresis (NE) in combination with standard therapy
Study: 8522381
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg twice daily
Study: 23608797
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition fluid (30 ml·kg(‐1)·d(‐1))
Study: 23608797
Drug: Traditional intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional intestinal preparation (fasting, oral antibiotic, cleaning enema)
Study: 23608797
Drug: Traditional bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional bowel preparation
Study: 21389858
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of oral flucloxacillin
Study: 19637415
Drug: Atazanavir and
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir and ritonavir combination
Study: 19637415
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of lopinavir and ritonavir
Study: 27376466
Drug: TNF‐α inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α inhibitors
Study: 14702268
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg)
Study: 29029131
Drug: AA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AA infusion
Study: 22123096
Drug: Oral 9-THC
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 9-THC 10 mg QID
Study: 24661235
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 4% articaine with 1 : 100 000 epinephrine
Study: 24661235
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of 4% articaine with 1 : 100 000 epinephrine
Study: 24661235
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 4% articaine with 1 : 100 000 epinephrine (initial IANB)
Study: 12949684
Drug: Impaza (antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaza (antibodies to endothelial NO synthase in ultralow doses)
Study: 11004016
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing peptide-2 (1 microg/kg)
Study: 11004016
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-arginine and growth hormone-releasing peptide-2
Study: 31678060
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with 940nm, 2.5W, 120s, 85.71J/cm2, 0.89W/cm2, three times per week for two weeks (G1)
Study: 31678060
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with 940nm, 4.1W, 120s, 68.33J/cm2, 0.58W/cm2, three times per week for two weeks (G2)
Study: 19812066
Drug: Intra-partum single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-partum single-dose nevirapine
Study: 16901024
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection into the musculature adjacent to the wound
Study: 16901024
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection into the musculature adjacent to the wound
Study: 15293866
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg (oral)
Study: 30005748
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of level overlap and color coding
Study: 17186726
Drug: Drug cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug cupping therapy (DCT) with Liuwei Dihuang Pill (LDP)
Study: 17186726
Drug: Common cupping
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common cupping therapy without drug
Study: 1289921
Drug: Intramuscular desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular desipramine (DMI) 75 mg
Study: 6549160
Drug: Allopurinol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (20 mg/kg/day orally for 3 days)
Study: 31883766
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline administered at the same rate for the same duration
Study: 19678557
Drug: Spiritual-hypnosis assisted
Normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spiritual-hypnosis assisted therapy (SHAT)
Study: 31560227
Drug: Bulking laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulking laxative and probiotic
Study: 31560227
Drug: Osmotic laxative
Normalized name: HYPEROSMOTIC LAXATIVES
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic laxative
Study: 27317162
Drug: L-carnitine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1000 mg/d)
Study: 19036981
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of the selective NE‐reuptake inhibitor reboxetine (RBX)
Study: 10807817
Drug: salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol inhalation via pMDI
Study: 10807817
Drug: salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol inhalation via pMDI + spacer
Study: 10807817
Drug: placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhalation
Study: 10807817
Drug: salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol inhalation via Autohaler
Study: 8614273
Drug: ENA 713
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENA 713 12 mg/day bid (n=20)
Study: 1940775
Drug: Lovastatin treatment
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin treatment
Study: 29544728
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 80/14.4/10 μg
Study: 22504462
Drug: 0.01 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg/h background infusion plus 0.01 mg/kg bolus (BI)
Study: 22504462
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg bolus-only morphine (B0)
Study: 20480794
Drug: Onion extract
Normalized name: Onion Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion extract gel (OE)
Study: 20480794
Drug: 0.5% hydrocortisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hydrocortisone, silicone and vitamin E lotion (HSE)
Study: 17638395
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 40 mg once daily
Study: 17638395
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg once daily + Hydrochlorothiazide 12.5 mg once daily
Study: 17638395
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg once daily (initial treatment)
Study: 16097995
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.d. for 5 days
Study: 7044013
Drug: Molsidomine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (3 x 2 mg/day)
Study: 22342506
Drug: Long agonist
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long agonist half-dose protocol
Study: 22342506
Drug: Short agonist
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short agonist protocol without pretreatment
Study: 16490579
Drug: IDD-P fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDD-P fenofibrate 160-mg tablet plus atorvastatin 10-mg tablet
Study: 16490579
Drug: IDD-P fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDD-P fenofibrate 160-mg tablet plus simvastatin 10-mg tablet
Study: 11391844
Drug: MSP (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP (250 mg mefloquine, 500 mg sulphadoxine, and 25 mg pyrimethamine per tablet)
Study: 11391844
Drug: CQ (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ (150 mg chloroquine base per tablet)
Study: 1379523
Drug: Fazarabine (Ara-AC)
Normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazarabine (Ara-AC) at a dose of 2.00 mg m‐2 h‐1
Study: 26094591
Drug: Younger age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger age and higher oral HPV16 copy number
Study: 24274358
Drug: Instaflex™ Joint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instaflex™ Joint Support (3 colored gel capsules per day for 8 weeks)
Study: 24274358
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 colored gel capsules per day for 8 weeks)
Study: 21136237
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (GLA)
Study: 21136237
Drug: Insulin Detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin Detemir (DET)
Study: 18234045
Drug: eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eletriptan 40 mg (E40) and E80
Study: 10907666
Drug: Olanzapine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (daily dose: 18.3 mg)
Study: 10907666
Drug: Sertindole (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (daily dose: 16 mg)
Study: 10907666
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotic drugs (n=12)
Study: 1800390
Drug: Bismuth subnitrate
Normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subnitrate (3 x 700 mg/d)
Study: 1800390
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 x 800 mg/d)
Study: 25866027
Drug: Graded single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded single radiation doses with fixation after 24 h (dose-response)
Study: 18167291
Drug: Traditional pericardial
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional pericardial monocuspid valve patch
Study: 15451058
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (45 mg zinc as gluconate daily for 8 weeks)
Study: 8180524
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg i.v. injection followed by 20 mg tablet once daily for 6 days)
Study: 8180524
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg i.m. injection followed by 50 mg tablet 4 to 6 hours postoperatively and 50 mg three times daily for 6 days)
Study: 8180524
Drug: Tenoxicam (suggested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (suggested 40 mg dose at induction of anesthesia)
Study: 3540870
Drug: Codeine 60
Normalized name: codeine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 60 mg at all three doses
Study: 3540870
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at all three doses
Study: 21724341
Drug: Weekly marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly marijuana users
Study: 15450839
Drug: New 2-octylcyanoacrylate
Normalized name: 2-octylcyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New 2-octylcyanoacrylate formulation
Study: 15450839
Drug: Old 2-octylcyanoacrylate
Normalized name: 2-octylcyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old 2-octylcyanoacrylate formulation
Study: 18787216
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg twice daily)
Study: 11170948
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g intravenously twice daily)
Study: 9924006
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Cu/l (Control)
Study: 9924006
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Cu/l
Study: 9924006
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg Cu/l
Study: 2318372
Drug: Non-pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological treatment consisting of monthly check-ups, home blood pressure measurements, and lifestyle advice (salt restriction, weight reduction, physical activity, reduction of alcohol and tobacco)
Study: 30640655
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.375% ropivacaine (Group A)
Study: 22727783
Drug: Pre-treatment craving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment craving measured using the Obsessive subscale of the Obsessive Compulsive Drinking Scale
Study: 22727783
Drug: Pre-treatment depressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment depressive mood
Study: 20932667
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) - three cycles of cisplatin-based chemotherapy followed by CHART
Study: 17401488
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of daclizumab, mycophenolate mofetil (MMF), and prednisone (GII, N = 33)
Study: 10834687
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered at 8-hr intervals through nasogastric tube)
Study: 2876326
Drug: Homoeopathic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic preparation of mixed grass pollens
Study: 31755993
Drug: Topical omiganan
Normalized name: Omiganan
DrugBank: Omiganan (DB06610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical omiganan 2.5%
Study: 27571256
Drug: Dexmedetomidine (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (continuous infusion at a rate of 0.1 μg kg h; n = 38)
Study: 12795572
Drug: Family-focused psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused psychoeducational therapy (n = 28)
Study: 1352930
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily for 4 weeks, then 40 mg daily for another 4 weeks
Study: 30113651
Drug: Dapagliflozin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin at 10 mg
Study: 30113651
Drug: Empagliflozin at
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin at 10 mg
Study: 12826169
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vitamin D plus calcium at the same dose)
Study: 8799780
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 g oral dose of azithromycin (Group A)
Study: 8799780
Drug: Standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard duration therapy (Group S)
Study: 1386071
Drug: Fenoterol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.1 mg/kg) plus ipratropium bromide (50 micrograms)
Study: 1386071
Drug: Fenoterol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.1 mg/kg) and placebo
Study: 6364761
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (CABG)
Study: 30821649
Drug: Telephone-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based Cognitive Behavioral Therapy (CBT)
Study: 29730798
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without a nerve block)
Study: 27543364
Drug: Melatonin cream
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin cream 12.5%
Study: 27543364
Drug: Melatonin cream
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin cream 0.5%